Investing

MetLife, MiMedx Group Fall into Friday's 52-Week Low Club

Geerati / Getty Images

July 6, 2018: Here are four stocks trading with heavy volume among 32 equities making new 52-week lows in Friday’s session. On the NYSE advancers led decliners by about 2.7 to 1 and on the Nasdaq, advancers led decliners by about 2.35 to 1.

Regulus Therapeutics Inc. (NASDAQ: RGLS) traded down 67% Friday to set a new 52-week low of $0.34 after closing Thursday at $0.73. The stock’s 52-week high is $1.52. Volume was more than 25 times the daily average of about 220,000 shares. The company announced a strategic update and restructuring after markets closed Thursday.

MagneGas Corp. (NASDAQ: MNGA) dropped about 5.7% Friday to post a new 52-week low of $0.33. Shares closed at $0.35 on Thursday and the stock’s 52-week high is $22.95. Volume totaled around 3.8 million shares was more than double the daily average. The company had no specific news.

MiMedx Group Inc. (NASDAQ: MDXG) fell about 7.7% Friday to post a new 52-week low of $3.47. Shares closed at $3.76 on Thursday. The 52-week high is $18.25. Volume of around 3.5 million was about 15% above the daily average. The company had no specific news.

MetLife Inc. (NYSE: MET) traded down about 1.1% Friday and posted a new 52-week low of $43.09 after closing Thursday at $43.56. The stock’s 52-week high is $55.91. Volume totaled around 2.4 million, less than half the daily average. The company had no specific news.

Sponsored: Attention Savvy Investors: Speak to 3 Financial Experts – FREE

Ever wanted an extra set of eyes on an investment you’re considering? Now you can speak with up to 3 financial experts in your area for FREE. By simply
clicking here
you can begin to match with financial professionals who can help guide you through the financial decisions you’re making. And the best part? The first conversation with them is free.


Click here
to match with up to 3 financial pros who would be excited to help you make financial decisions.

Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.